Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

YK-176 is a newly isolated 2'-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase, produced by Aspergillus nidulans. In a cooperative phase I study, YK-176 was administered to 22 patients, comprising 18 with adult T-cell leukemia-lymphoma (ATL), two with cutaneous T-cell lymphoma (CTCL), one with lymphoblastic lymphoma of T-cell type and one with carcinoma of the uterine cervix. Doses of YK-176 ranged from 3.0 to 9.0 mg/m2 and were given intravenously for three consecutive days. General malaise, anorexia, nausea, vomiting and low grade fever were frequently encountered, but were transient and not dose-related. At all dose levels hematological toxicities were mild. Two of seven patients receiving 7.0 mg/m2 for three consecutive days developed hepatocellular enzyme elevations (grade 2) and one patient, proteinuria (grade 2). One of two patients given 9.0 mg/m2 for three consecutive days manifested a life-threatening (grade 4) disturbance of consciousness and dyspnea, presumably ascribable to the drug-related toxicity of YK-176. The results suggest that 7.0 mg/m2 i.v. for three consecutive days is the maximum acceptable dose of YK-176. Central nervous system, pulmonary and possibly renal toxicities appeared to be dose-limiting. Out of the 20 patients evaluable for therapeutic response, partial remissions were observed in four, three with ATL and one with CTCL, who received less than 7.0 mg/m2 for three consecutive days. We conclude that YK-176 is an active agent against ATL at doses that may not be associated with prohibitive toxicity. A starting dose of 5.0 mg/m2 for three consecutive days is recommended for further phase II studies on ATL.
 ...
PMID:Phase I study of YK-176 (2'-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. The DCF Study Group. 151 64

A patient with FIGO stage IIIb adenocarcinoma of the uterine cervix (moderately differentiated, endocervical type) underwent an exploratory laparotomy because of a direct cancer invasion to the bladder wall, and then she was treated with consecutive intraarterial (IA) CDDP (10 mg/day) combined with continuous IA 5-FU (250 mg/day). Six weeks after, CR (complete response) was obtained by this IA chemotherapy (total dose; 5-FU: 10,500 mg, CDDP: 300 mg). Further 5-weeks-IA chemotherapy was added to keep the "CR" effect (final total dose; 5-FU: 19,250 mg, CDDP: 500 mg). The only toxic sign was a mild nausea. The patient's PS (performance status) was 0 (normal activity) and thereafter she could undergo a "curative" radical hysterectomy. The cancer invasion to the bladder wall observed at the first exploratory surgery completely disappeared histologically as well as macroscopically. In obtained material, small "viable" cancer focus was found in the cervical canal but the margin was free, and all nodes were negative. Postoperatively, the patient has receiving a continuous IA 5-FU (125 mg/day) for 13 months as a maintenance and she is free of disease (NED) with a normal activity (PS = 0). The present treatment modality is considered to be promising for advanced cervical adenocarcinoma having a poor prognosis due to its low sensitivity to radiotherapy.
 ...
PMID:[Effective continuous intraarterial chemotherapy for a patient with FIGO stage IIIb cervical adenocarcinoma invasing the bladder wall]. 226 37

Advanced squamous cell carcinoma of the head and neck, lung, esophagus, and uterine cervix is still a challenging cancer to the medical practice. We have treated 23 such patients with a combination of cis-platinum, vincristine, and peplomycin. Cis-platinum was given at a dose of 60 mg/m2 on day 1, and 1.0 mg/m2 of vincristine was given on day 3, followed 6 hours later by peplomycin 10 mg/day by continuous infusion iv or sc over the next 5 days. This combination was given every 3 weeks. The overall response rate was 71% for 17 evaluable patients, including one complete response. The median duration of response and survival was 2 and 5 months, respectively. Six other patients with esophageal and cervical carcinoma were treated with two cycles of this combination followed by radical radiation therapy or surgery. Five of them achieved significant response prior to radical treatment. Major side effects were nausea, vomiting, alopecia, and mild myelotoxicity, which were acceptable. This regimen, with a high response rate and acceptable toxicity, warrants further investigation.
 ...
PMID:Phase II trial of cis-diamminedichloroplatinum (cis-platinum), vincristine, and peplomycin for advanced squamous cell carcinoma. 244 Dec 7

Surgery and radiation therapy are major treatments for carcinoma of the uterine cervix. However, there has been little improvement in survival recently. Since 1982, we have introduced multiagent chemotherapy consisting of cis-platinum, vincristine and peplomycin (CVP) to control systemic disease and to do cytoreduction prior to operation and/or radiation therapy. Our results are as follows. Thirty-one patients have been treated with CVP. Among eleven patients initially treated with CVP, 7 patients responded well to this regimen alone, including three patients who entered complete clinical remission. This indicates that this regimen is effective against carcinoma of the uterine cervix. Two patients who were thought to be candidates for radical hysterectomy became able to have less extensive surgery following CVP treatment. It is difficult for this CVP combination to control bulky tumors within previously radiated fields, probably because of poor vascularity due to pelvic fibrosis caused by radiation. Metastatic disease were also able to be controlled by this combination especially in two patients with pulmonary metastases. Nausea, vomiting and mild myelosuppression were frequently encountered, but they were tolerated well by the patients. However, great care must be taken in using peplomycin when the cumulative dose becomes large.
 ...
PMID:[Cis-platinum, vincristine and peplomycin (CVP) therapy for carcinoma of the uterine cervix]. 246 61

It is estimated that in 1988 there will be 12,900 cancers of the uterine cervix, representing 2.6% of cancers in women. Radiation therapy has been the primary mode of therapy/palliation; for the past 15-20 years survival results achieved with radiotherapy have plateaued. Attempts have been made to find agents to use with radiation aimed at decreasing recurrence and increasing survival. Phase II studies suggest cisplatin may be an excellent agent to combine with radiotherapy. This study was performed to evaluate the toxicity of this combination. Between December 10, 1980, and August 29, 1986, nine patients with advanced cervical cancer and poor prognosis and one patient with recurrent disease were enrolled. The Gynecologic Oncology Group (GOG) criteria for adverse effects were used in this study. Hematologic, gastrointestinal, genitourinary, and skin parameters were examined. Most adverse criteria had a score of 2 or less. Grade 2 nausea/vomiting was the most frequent problem. Anemia was the next most frequent and was the most serious problem encountered. Overall, the toxicity was acceptable; therefore it seems appropriate to proceed to larger studies to evaluate efficacy.
 ...
PMID:Advanced cervical cancer therapy: concurrent radiation therapy and cisplatin chemotherapy for advanced cervical cancer--a toxicity report. 258 27

A phase II study of 5-FU tablet for 52 patients with cancer of the uterine cervix was undertaken by a cooperative study group consisting of 13 institutions. The clinical response rate in 44 evaluable cases was 31.8% (CR: 3 cases, PR: 11 cases, MR: 2 cases, NC: 19 cases and PD: 9 cases). Efficacy rates of 5-FU tablet according to lesion sites were 44.4% in the uterine cervix, 42.9% in the vaginal wall and cut vaginal end, 25.0% in the lymph nodes and 16.7% in the lung. Histologically, the effectiveness rate was 26.9% for large-cell, non-keratinizing-type-carcinoma, 42.9% for small-cell, non-keratinizing-type, and 60.0% for the keratinizing-type of squamous cell carcinoma. One of three adenocarcinoma cases (33.3%) showed improvement. Some adverse effects were observed in 16 (32.0%) of 50 evaluable cases. A large proportion of the adverse effects were gastro-intestinal disorders, such as nausea, vomiting and anorexia. These results suggested that 5-FU tablet is a useful chemotherapeutic agent against carcinoma of the uterine cervix.
 ...
PMID:[Phase II study of 5-FU tablets in cancer of the uterine cervix]. 360 56

Metastatic involvement of the myocardium is a rare premorbid diagnosis. Multiple examinations were performed on a 43-year-old woman who presented with ischemic chest pain, palpitations, and nausea. Twelve months previously, a poorly differentiated squamous cell carcinoma of the uterine cervix was removed with no evidence of metastases or residual tumor. Following numerous investigations, a provisional diagnosis of cardiac tumor was made. At operation, involvement of the septum, inferior wall, and apex with some extension into the distal anterior wall was noted. Histology confirmed nonkeratinizing cell carcinoma in keeping with metastases from the uterine cervix.
 ...
PMID:Metastatic uterine cervical cell carcinoma to myocardium. 376 43

The side effects of nausea and diarrhea have frequently been observed following the administration of prostaglandin E2 or F2alpha for the induction of labor or abortion. The oral administration of prostaglandin E1 to volunteers has elicited similar reactions. Reports that aspirin might relieve some types of nausea or diarrhea led to the testing of aspirin against the diarrhea induced by the radiation therapy of cancer of the uterine cervix. The treatment of cervical cancer by a combination of external radiation and radium often produces diarrhea, probably because loops of bowel in the path of X-rays are damaged. 15 women between the ages of 47 and 65 who had been irradiated for cancer of the cervix and who had developed diarrhea that failed to respond to conventional therapy participated in a preliminary trial. When conventional therapy failed, it was abandoned and each patient was given 900 mg of soluble aspirin B.P. ("Slfrin") by mouth, 4 times daily. In 4 patients the diarrhea cleared up completely within 24 hours of taking the aspirin. The diarrhea was improved in 8 patients, although in 2 it relapsed 48 hours after improvement was 1st observed. Colicky pain which accompanied diarrhea in 3 patients disappeared during aspirin therapy. 1 patient who had severe nausea experienced marked relief. The findings indicate that aspirin may be of value in the treatment of diarrhea induced by radiation. Since prostaglandin synthesis can be provoked by many different forms of stimulation, and because aspirin at low concentrations inhibits this synthesis, it is suggested that prostaglandins are involved in radiation induced diarrhea. A carefully controlled trial of aspirin in the treatment of radiation induced diarrhea is now being conducted.
 ...
PMID:Aspirin in radiation-induced diarrhoea. 412 59

The aim of this quality-assurance study was to assess how patients with cancer of the uterine cervix experience different aspects of care during brachytherapy treatment. Twenty patients scheduled for intrauterine brachytherapy using an afterloading technique and 20 controls with other gynaecological malignancies, undergoing a gynaecological palpation under anaesthesia, were given a questionnaire to complete. The questionnaire consisted of ten items related to information received, pain, sleep, nausea and food intake. Each item was constructed as a statement to be answered on a five-point Likert-like scale, with alternatives ranging from very positive to very negative. Among the results, 17 of the 20 brachytheraphy patients reported that they experienced great anxiety before admission. The corresponding figure for the control group was 9/20 (P < 0.01). As regards pain, 13/20 and 0/20, respectively, suffered from moderate or severe pain (P = 0.0000), despite standard analgesic medication. Twelve of the brachytherapy patients praised the ordinary hospital liquid foods, whereas 8/20 would clearly have preferred alternative menus. In the control group 18/20 approved of the food and 2/20 did not (P < 0.05). The results clearly underline the importance of quality-assurance studies that focus on the side-effects of treatment. This study has resulted in a new care programme with intensified prophylactic treatment of pain and nausea and a novel form of "picking food", i.e. pieces of vegetables, meat and chips that are easy to eat in a supine position.
 ...
PMID:Pain, nausea and anxiety during intra-uterine brachytherapy of cervical carcinomas. 765 83

The aim of this study was to assess acute toxicities of concurrent low-dose daily cisplatin and extended-field radiation therapy (EFRT) for carcinoma of the uterine cervix. Fifteen women with cervical cancer who were treated with concurrent daily low-dose cisplatin and EFRT were analyzed. Daily cisplatin dose was fixed to 8 mg/m(2), which was determined in the preceding phase I study using pelvic radiotherapy. Twelve patients underwent either combined external beam radiation therapy and intracavitary brachytherapy or external beam radiation therapy alone. Three other patients were treated with adjuvant chemoradiotherapy after surgery. A total dose of EFRT ranged from 40 to 45 Gy, with an additional boost to the gross tumor volume up to 50.4-55 Gy. A median total dose of cisplatin during entire radiation therapy course was 224 mg/m(2) (range, 200-240 mg/m(2)). In 14 of 15 patients (93%), daily cisplatin could be delivered continuously as planned without any modification. Administration of cisplatin had to be interrupted in only one patient for only 3 days. Fourteen patients developed grade 2 or worse leukopenia including five after treatment, grade 2 in four, grade 3 in eight, and grade 4 in two. Grade 3 thrombocytopenia was observed in three patients. Grade 2 or worse anemia was observed in 12. Three patients had grade 3 nonhematologic toxicities, diarrhea in two, and nausea/vomiting in one. Although moderate to severe hematologic toxicities are common, this study suggests that concurrent low-dose daily cisplatin and EFRT are feasible. A cumulative cisplatin dose of greater than 200 mg/m(2) during radiation therapy could be achieved by using daily cisplatin dose of 8 mg/m(2).
 ...
PMID:Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix. 1746 53


1 2 Next >>